Zimmer Biomet Holdings Inc
NYSE:ZBH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Zimmer Biomet Holdings Inc
Additional Paid In Capital
Zimmer Biomet Holdings Inc
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Zimmer Biomet Holdings Inc
NYSE:ZBH
|
Additional Paid In Capital
$10.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
2%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Additional Paid In Capital
$21.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
2%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Additional Paid In Capital
$2.8B
|
CAGR 3-Years
11%
|
CAGR 5-Years
13%
|
CAGR 10-Years
11%
|
|
|
Stryker Corp
NYSE:SYK
|
Additional Paid In Capital
$2.6B
|
CAGR 3-Years
8%
|
CAGR 5-Years
8%
|
CAGR 10-Years
7%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Additional Paid In Capital
$10.8B
|
CAGR 3-Years
12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
12%
|
|
Zimmer Biomet Holdings Inc
Glance View
Zimmer Biomet Holdings Inc. stands as a prominent player in the medical device industry, specializing in musculoskeletal healthcare. Emerging from a rich legacy that dates back to its origins in the early 20th century, the company has carved out its niche by innovating in the orthopedic reconstruction sector. Zimmer Biomet operates primarily through designing, manufacturing, and marketing a comprehensive range of orthopedic products, which include joint replacement implants, such as knees, hips, and shoulders, as well as products used for fracture fixation and bone growth stimulation. The innovative edge of Zimmer Biomet lies in its commitment to improving patient outcomes and enhancing the quality of life through advanced surgical and robotic technologies. The company invests significantly in R&D to maintain its competitive edge, constantly pushing the boundaries in personalized solutions and minimally invasive surgery. The company generates revenue by selling its orthopedic and surgical products directly to hospitals, surgical centers, and healthcare providers worldwide. Zimmer Biomet's business model is heavily reliant on the relationships it builds with orthopedic surgeons and healthcare institutions, positioning itself as an essential partner in delivering sophisticated solutions for musculoskeletal health. By focusing on comprehensive, integrated solutions, Zimmer Biomet not only addresses the immediate surgical needs but also engages with the continuum of care in rehabilitation and patient recovery. The company’s strategic acquisitions, sophisticated product pipeline, and global market presence enable it to capture a significant share of the medical device market, ensuring its role as a stalwart in transforming the future of healthcare.
See Also
What is Zimmer Biomet Holdings Inc's Additional Paid In Capital?
Additional Paid In Capital
10.2B
USD
Based on the financial report for Dec 31, 2025, Zimmer Biomet Holdings Inc's Additional Paid In Capital amounts to 10.2B USD.
What is Zimmer Biomet Holdings Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
2%
Over the last year, the Additional Paid In Capital growth was 1%. The average annual Additional Paid In Capital growth rates for Zimmer Biomet Holdings Inc have been 2% over the past three years , 2% over the past five years , and 2% over the past ten years .